Scheduled versus Symptom-based Follow-up after Intradetrusor Onabotulinum Toxin A

Thursday, October 5, 2023

3:30 PM – 4:30 PM US PST

Location: B111

Scientific Table Presenter(s)

Nicole T. Norby, MD (she/her/hers)

Resident
Viriginia Tech Carilion Clinic
Roanoke, Virginia, United States

Co-Author(s)

HS

Hunter D. Sharp, MS

Biostatistician
Health Analytics Research, Carilion Clinic
Roanoke, Virginia, United States
SE

Sarah Evans, MD (she/her/hers)

Primary Investigator
Virginia Tech Carilion Clinic
Roanoke, Virginia, United States

Disclosure(s):

Nicole T. Norby, MD: No financial relationships to disclose

Hunter D. Sharp, MS: No financial relationships to disclose

Sarah Evans, MD: No financial relationships to disclose

This Table Talk will discuss a study about different follow-up strategies (scheduled versus only if needed) for patients after intradetrusor Botox. Between our two study groups - those with scheduled versus patient-initiated follow-up - we looked at common complications and found no difference between rates of UTIs, rates of catheterization, ED visits, office phone calls, and/or unplanned office visits six weeks after procedure. Patient-initiated follow-up can likely be safely used to reduce healthcare burden.